Search Result

Results for "

Peptidic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenylate Cyclase (1) Amino Acid Oxidase (1) Aminopeptidase (3) Angiotensin Receptor (1) Antibiotic (2) Apelin Receptor (APJ) (1) Apoptosis (4) Arrestin (2) Bacterial (2) Bcl-2 Family (4) Beta-secretase (2) Cadherin (1) Calcium Channel (2) Caspase (2) Cathepsin (1) CCR (1) Complement System (4) CRFR (1) CXCR (2) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (1) Drug Derivative (1) ERK (1) HCV (1) HIV (1) HIV Protease (2) IAP (2) Ligands for E3 Ligase (2) MMP (6) Neurokinin Receptor (2) Neuropeptide B/W Receptor (2) Neurotensin Receptor (1) Opioid Receptor (2) Oxytocin Receptor (1) PAI-1 (2) Peptide-Drug Conjugates (PDCs) (2) PI3K (3) Potassium Channel (1) Reference Standards (4) SARS-CoV (6) TGF-beta/Smad (3) Thrombin (2) Vasopressin Receptor (3) VEGFR (1) Virus Protease (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (17) Cardiovascular Disease (8) Endocrinology (2) Infection (9) Inflammation/Immunology (14) Metabolic Disease (6) Neurological Disease (12)

By Targets:

Adenylate Cyclase (1)

Amino Acid Oxidase (1)

Aminopeptidase (3)

Angiotensin Receptor (1)

Antibiotic (2)

Apelin Receptor (APJ) (1)

Apoptosis (4)

Arrestin (2)

Bacterial (2)

Bcl-2 Family (4)

Beta-secretase (2)

Cadherin (1)

Calcium Channel (2)

Caspase (2)

Cathepsin (1)

CCR (1)

Complement System (4)

CRFR (1)

CXCR (2)

Cyclin G-associated Kinase (GAK) (1)

Cyclophilin (1)

Drug Derivative (1)

ERK (1)

HCV (1)

HIV (1)

HIV Protease (2)

IAP (2)

Ligands for E3 Ligase (2)

MMP (6)

Neurokinin Receptor (2)

Neuropeptide B/W Receptor (2)

Neurotensin Receptor (1)

Opioid Receptor (2)

Oxytocin Receptor (1)

PAI-1 (2)

Peptide-Drug Conjugates (PDCs) (2)

PI3K (3)

Potassium Channel (1)

Reference Standards (4)

SARS-CoV (6)

TGF-beta/Smad (3)

Thrombin (2)

Vasopressin Receptor (3)

VEGFR (1)

Virus Protease (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (17)

Cardiovascular Disease (8)

Endocrinology (2)

Infection (9)

Inflammation/Immunology (14)

Metabolic Disease (6)

Neurological Disease (12)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106178

PMX-53 5+ Cited Publications 3D53	Complement System	Cardiovascular Disease Inflammation/Immunology Cancer
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC₅₀ of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects .

HY-143216

Ensitrelvir 10+ Cited Publications S-217622	SARS-CoV Virus Protease	Infection
Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC₅₀=13 nM) .

HY-P1717

AMY-101 5+ Cited Publications Cp40	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P0118B

Disitertide diammonium Maximum Cited Publications 18 Publications Verification P144 diammonium	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) diammonium is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer .

HY-137322

THX-B	Neurotensin Receptor	Neurological Disease Metabolic Disease
THX-B is a potent and non-peptidic p75 ^NTR (neurotrophin receptor p75) antagonist. THX-B can be used in the research of diabetic kidney disease, neurodegenerative and inflammatory disorders .

HY-103351

Cathepsin G Inhibitor I	Cathepsin	Inflammation/Immunology
Cathepsin G Inhibitor I (Compound 7) is a potent, selective, reversible, competitive, non-peptidic Cathepsin G inhibitor (IC₅₀ = 53 nM; K_i = 63 nM). Cathepsin G Inhibitor I can be used in research related to immune disorders .

HY-119850

Aladorian ARM036; S44121	Calcium Channel	Cardiovascular Disease
Aladorian (ARM036; S44121) is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian improves cardiomyocyte Ca²⁺ homeostasis independent of dystrophin restoration. Aladorian attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy .

HY-108624

CYM 50769	Neuropeptide B/W Receptor	Cardiovascular Disease Inflammation/Immunology
CYM 50769 is a non-peptidic selective antagonist of neuropeptides B and W receptor 1 (NPBWR1). CYM 50769 can attenuates the NPW-23-induced cell proliferation in ATDC5. CYM 50769 can be used for researching endochondral bone formation .

HY-P0118

Disitertide Maximum Cited Publications 18 Publications Verification P144	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer .

HY-P1717B

AMY-101 acetate 5+ Cited Publications Cp40 acetate	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-P1717A

AMY-101 TFA 5+ Cited Publications Cp40 TFA	Complement System SARS-CoV	Inflammation/Immunology
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .

HY-10472

LY2811376 10+ Cited Publications	Beta-secretase	Neurological Disease
LY2811376 is the first orally available non-peptidic β-secretase (BACE1) inhibitor with IC₅₀ of 239 nM-249 nM, that acts to decrease Aβ secretion with EC₅₀ of 300 nM, and demonstrates to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin.

HY-A0279A

Pristinamycin IA 1 Publications Verification Mikamycin B; Mikamycin IA	Bacterial Antibiotic	Infection
Pristinamycin IA (Mikamycin B) is a cycle-peptidic macrolactone antibiotic. Pristinamycin IA is a substrate of P-glycoprotein and inhibits its function. Pristinamycin IA is active against StaphyloEoccus and Srreptococcus .

HY-143216A

Ensitrelvir fumarate 10+ Cited Publications S-217622 fumarate	SARS-CoV Virus Protease	Infection
Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC₅₀=13 nM) .

HY-P1682A

Balixafortide TFA 1 Publications Verification POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-122542

PPACK	PAI-1 Thrombin	Inflammation/Immunology
PPACK is a potent, peptidic inhibitor targeting thrombin and granzyme GZMK. PPACK specifically blocks the activities of thrombin and GZMK, thereby inhibiting thrombin-mediated PAR-1 cleavage, as well as downstream inflammatory and procoagulant signaling pathways. Through stabilizing IκB proteins, blocking NF-κB activation and reducing systemic levels of proinflammatory/procoagulant biomarkers, PPACK exerts multiple effects including anti-inflammatory, antithrombotic, barrier repair, and inhibition of atherosclerotic plaque progression. PPACK binds to platelets without interference from kininogen, effectively limiting acute thrombus growth and reducing eosinophil infiltration and goblet cell hyperplasia in asthma models. PPACK is an important tool molecule for investigating the mechanisms of atherosclerosis, asthma and related thromboinflammatory diseases .

HY-P1682

Balixafortide 1 Publications Verification POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P1107A

Antisauvagine-30 TFA 4 Publications Verification aSvg-30 TFA	CRFR	Neurological Disease
Antisauvagine-30 TFA (aSvg-30 TFA) is a potent, highly selective and competitive CRF₂ receptor peptidic antagonist. Antisauvagine-30 TFA exhibits a K_d of 1.4 nM and 150 nM for mCRFR2β and CRFR1, respectively .

HY-12168

Tanomastat BAY 12-9566	MMP	Cancer
Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The K_i values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models .

HY-108579

UCL 1684 dibromide	Potassium Channel	Cardiovascular Disease
UCL 1684 (dibromide) is a first nanomolar, non-peptidic small conductance calcium-activated potassium (SK) channel blocker. UCL 1684 (dibromide) is effective in preventing the development of atrial fibrillation due to potent atrial-selective inhibition of I_Na. UCL 1684 (dibromide) causes atrial-selective prolongation of ERP secondary to induction of postrepolarization refractoriness .

HY-114091

PF-00356231 hydrochloride 2 Publications Verification	MMP	Inflammation/Immunology
PF-00356231 hydrochloride is a specific, non-peptidic, non-zinc chelating ligand and inhibitor of matrix metalloproteinase MMP-12 (IC₅₀=1.4 μM). PF-00356231 hydrochloride binds to MMP-12 and forms PF-00356231/MMP-12 complex. PF-00356231 hydrochloride shows potency against MMP-13, MMP-8, MMP-9, MMP-3 with IC₅₀s of 0.00065, 1.7, 0.98, 0.39 μM, respectively .

HY-18006

NKP608 1 Publications Verification	Neurokinin Receptor Wnt Bcl-2 Family β-catenin Cyclin G-associated Kinase (GAK) VEGFR Caspase Cadherin Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
NKP608 is a non-peptidic derivative of 4-aminopiperidine, a highly selective, orally active, neurokinin-1 (NK₁) receptor antagonist with IC₅₀ of 2.6 nM. NKP608 is active both in vitro and in vivo, showing extremely low affinity for NK₂, NK₃ receptors. NKP608 exerts its effects by blocking the NK₁ receptor, regulate cell proliferation and apoptosis, affect neurotransmitter functions and gastric mucosal repair mechanisms, and suppress the Wnt/β-catenin pathway in antitumor research. NKP608 is applicable to research related to various diseases, including cough, anxiety disorders, depression, gastric mucosal injury, and colorectal cancer .

HY-101580

Paliroden SR 57667	Drug Derivative	Neurological Disease
Paliroden is an orally bioactive neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines, used for treatment of Alzheimer's Disease and Parkinson's.

HY-160239

HFI-437	Aminopeptidase	Neurological Disease
HFI-437 is a potent non-peptidic insulin-regulated aminopeptidase (IRAP) inhibitor with a K_i of 20 nM. HFI-437 is a cognitive enhancer .

HY-P10759

DTS-201 sodium	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

HY-P0077

Merotocin	Oxytocin Receptor	Endocrinology
Merotocin is a selective, short-acting peptidic oxytocin receptor agonist. Merotocin can be used to support lactation .

HY-P0118A

Disitertide TFA P144 TFA	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer .

HY-18694

CGS 27023A	MMP	Inflammation/Immunology
CGS 27023A is a non-peptidic and orally active MMP inhibitor with the K_i values of 43, 33, 20 and 8 nM for MMP-3, MMP-1, MMP-2 amd MMP-9, respectively. CGS 27023A prevents cartilage degradation in stromelysin-induced rabbit cartilage degradation model. CGS 27023A can be used for study of arthritis .

HY-33009

AS057278	Amino Acid Oxidase	Neurological Disease
AS057278 is a potent, selective, orally active and blood-brain barrier (BBB) penetrant non-peptidic D-amino acid oxidase (DAAO) inhibitor with an IC₅₀ value of 0.91 μM and EC₅₀ of 2.2-3.95 μM. AS057278 can normalize phencyclidine (PCP)-induced prepulse inhibition in mice. AS057278 can be used for researching schizophrenia .

HY-133036

APJ receptor agonist 1	Apelin Receptor (APJ)	Cardiovascular Disease
APJ receptor agonist 1, a biphenyl acid derivative, is a potent APJ receptor (APJ-R) agonist (EC₅₀s 0.093 and 0.12 nM for human and rat APJ-R, respectively). APJ receptor agonist 1 displays in vitro potency to apelin-13, the endogenous peptidic ligand for the APJ receptor. APJ receptor agonist 1 has the potential for the research of heart failure .

HY-101317A

TAN-67 SB-205607	Opioid Receptor	Metabolic Disease
TAN-67 (SB-205607) is a non-peptidic delta-opioid receptor agonist that exhibits significant antinociceptive activity in both diabetic and non-diabetic mice. TAN-67 demonstrates a marked and dose-dependent reduction in acetic acid-induced abdominal constrictions, with a notably stronger effect in diabetic mice compared to their non-diabetic counterparts. TAN-67's antinociceptive properties are primarily mediated through the activation of delta 1-opioid receptors, as indicated by the pronounced antagonism observed upon administration of a selective delta 1-opioid receptor antagonist.

HY-W338079

Ac-Asp-Glu-Val-Asp-pNA	Caspase	Others
Ac-Asp-Glu-Val-Asp-pNA is a peptidic substrate of caspase-3/7 .

HY-U00188

A81988 Abbott81988	Angiotensin Receptor	Cardiovascular Disease Endocrinology
A81988 is a potent, competitive, non-peptidic antagonist of angiotensin AT₁ receptors.

HY-151197

HIV protease-IN-1	HIV Protease	Infection
HIV protease-IN-1 (compound 1·succinate) is a potent HIV protease non-peptidic inhibitor, can be used to research AIDS .

HY-123270

RP23618	CCR	Infection Inflammation/Immunology
RP23618 is a non peptidic RANTES antagonist with the IC₅₀ of 3 μM. RP23618 inhibit RANTES-induced chemotaxis of THP-1 cells .

HY-100866B

F1324 acetate	Bcl-2 Family	Cancer
F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 acetate exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-100866

F1324	Bcl-2 Family	Cancer
F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC₅₀ of 1 nM. F1324 exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-P1810

c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-Agm	Vasopressin Receptor	Neurological Disease
c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-Agm is a is a potent, selective and short-acting peptidic V₂ receptor (V₂R) agonist with EC₅₀s of 0.25 and 0.05 nM for hV₂R and rV₂R, respectively .

HY-A0279AR

Pristinamycin IA (Standard) Mikamycin B (Standard); Mikamycin IA (Standard)	Reference Standards Bacterial Antibiotic	Infection
Pristinamycin IA (Standard) is the analytical standard of Pristinamycin IA. This product is intended for research and analytical applications. Pristinamycin IA (Mikamycin B) is a cycle-peptidic macrolactone antibiotic. Pristinamycin IA is a substrate of P-glycoprotein and inhibits its function. Pristinamycin IA is active against StaphyloEoccus and Srreptococcus[1].

HY-100866A

F1324 TFA	Bcl-2 Family	Cancer
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 TFA exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-P1809A

Velmupressin acetate c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2 acetate	Vasopressin Receptor	Metabolic Disease
Velmupressin (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2) acetate is a potent, selective and short-acting peptidic V₂ receptor (V₂R) agonist with EC₅₀s of 0.07 and 0.02 nM for hV₂R and rV₂R, respectively .

HY-P1809

Velmupressin c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2	Vasopressin Receptor	Metabolic Disease
Velmupressin (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2) is a potent, selective and short-acting peptidic V₂ receptor (V₂R) agonist with EC₅₀s of 0.07 and 0.02 nM for hV₂R and rV₂R, respectively .

HY-106154

DTS-201	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 (CPI-0004) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

HY-18694A

CGS 27023A free base	MMP	Inflammation/Immunology
CGS 27023A free base is a non-peptidic and orally active MMP inhibitor with the K_i values of 43, 33, 20 and 8 nM for MMP-3, MMP-1, MMP-2 amd MMP-9, respectively. CGS 27023A free base prevents cartilage degradation in stromelysin-induced rabbit cartilage degradation model. CGS 27023A free base can be used for study of arthritis .

HY-106982

Ezlopitant CJ-11,974	Neurokinin Receptor	Neurological Disease Metabolic Disease
Ezlopitant (CJ-11,974) is a selective, non-peptidic neurokinin-1 (NK-1)-receptor antagonist. Ezlopitant inhibits both acute and delayed emetic reactions induced by Cisplatin (HY-17394) in ferrets via acting on NK1 receptors in the central nervous system. Ezlopitant has the potential for pain, chemotherapy-induced emesis and irritable bowel syndrome research .

HY-130176

UFP-512	Opioid Receptor ERK Adenylate Cyclase	Neurological Disease
UFP-512 is a selective and potent σ-opioid receptor (DOP receptor) peptidic agonist with antidepressant- and anxiolytic-like effects. UFP-512 exhibits as a potent agonist on adenylyl cyclase inhibition and Erk1/2 activation. UFP-512 induces phosphorylation of DOP receptors on Ser ³⁶³ with a low desensitization of the cAMP pathway. UFP-512 is promising for research of mood disorders .

HY-12168B

(Rac)-Tanomastat (Rac)-BAY 12-9566	MMP	Cancer
(Rac)-Tanomastat ((Rac)-BAY 12-9566) is the racemate of Tanomastat. Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The K_i values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models .

HY-174320

SARS-CoV-2-IN-112	SARS-CoV	Infection
SARS-CoV-2-IN-112 (Compound 6f) is an orally active and non-peptidic SARS-CoV-2 main protease inhibitor with an IC₅₀ of 6.48 μM. SARS-CoV-2-IN-11 has potent antiviral activity with low cytotoxicity against WI-38 cells (IC₅₀: 53.81 μM). SARS-CoV-2-IN-112 can be used for coronaviruses COVID-19 research .

HY-119850A

Aladorian sodium ARM036 sodium; S44121 sodium	Calcium Channel	Cardiovascular Disease
Aladorian (ARM036; S44121) sodium is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian sodium stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian sodium improves cardiomyocyte Ca ²⁺ homeostasis independent of dystrophin restoration. Aladorian sodium attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian sodium can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy .

HY-114091A

PF-00356231	MMP	Inflammation/Immunology
PF-00356231 hydrochloride is a specific, non-peptidic, non-zinc chelating ligand and inhibitor of matrix metalloproteinase MMP-12 (IC₅₀=1.4 μM). PF-00356231 hydrochloride binds to MMP-12 and forms PF-00356231/MMP-12 complex. PF-00356231 hydrochloride shows potency against MMP-13, MMP-8, MMP-9, MMP-3 with IC₅₀s of 0.00065, 1.7, 0.98, 0.39 μM, respectively .

Cat. No.	Product Name	Target	Research Area